Andrew Stewart Coats

After qualifying in medicine in 1980, Stewart Coats started his career at St Vincent's Hospital, Melbourne under Professor David Penington and then the University of Oxford under Professor Peter Sleight. In 1991, he was appointed Senior Lecturer, supported by the British Heart Foundation, at the National Heart and Lung Institute [NHLI] under Professor Philip Poole-Wilson.

In 1996, he was appointed the Viscount Royston Professor of Cardiology at Imperial College. He was also honorary consultant physician at the Royal Brompton Hospital in London, and its Clinical Director for Cardiology and its Associate Medical Director. In 2002, Stewart Coats became the 17th Dean of the Faculty of Medicine at the University of Sydney.[5] In 2006, he was appointed Deputy Vice-Chancellor (External Communications) of the University of Sydney.[6] In 2009, Stewart Coats was appointed the second Norwich Research Park Professor-at-Large, second to Baron Solly Zuckerman.[7][8] In 2011, Stewart Coats was appointed chief executive officer of the Norwich Research Park. In 2013, he took up the position of Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK.[9][10][11]

Stewart Coats commenced his research career in hypertension, where he did some of the early work on the clinical value of 24-hour ambulatory blood pressure monitoring.[12][13] His subsequent career, forming the bulk of his more than 550 research papers, has been in the field of heart failure where he conducted the first ever randomised trial of exercise training in chronic heart failure.[14]

He coined the term "The Muscle Hypothesis", the now accepted explanation for the generation of exercise-limiting symptoms in chronic heart failure, but at the time a radical theory.[15]

He has been chairman or a member of the steering committee of many large-scale international drug trials that have influenced treatment of cardiovascular disease. These include the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial,[16] OPTIMAAL (angiotensin receptor antagonist in heart failure),[17] and SENIORS (management of heart failure in the elderly).[18]

He has published widely, with over 450 items on PubMed as of February 2011[19] and has been Editor-in-Chief of the International Journal of Cardiology since 1999.

In 2016, he was the keynote speaker at the International Conference of Undergraduate Research, held concurrently in Australia, the UK, Singapore, Malaysia, Japan, South Africa and the US.[20]

Stewart Coats was appointed chair of Australia's peak policy body for Health Informatics, the Australian Health Information Council (AHIC). He sat on many committees and chaired the New South Wales Ministerial Advisory Committee on Health and Medical Research (MACMHR).[21] In his three years as Deputy Vice-Chancellor in charge of External Relations and Development at Sydney, the university achieved the highest ever fund-raising total for any Australian university, in excess of A$50 million per year.[22]

Stewart Coats completed an MBA at London Business School and subsequently became a Fellow of the Australian Institute of Company Directors and a member of London's Institute of Directors. He has also been a board director of a number of private and public companies, including Myotec,[23] PsiOxus,[24] Lone Star Heart Inc.,[25] Centenary Institute, the Heart Research Institute, Cardiodirect (UK) Limited, the Woolcock Institute of Medical Research,[26] and the George Institute of International Health.[27][28]